Global Phosphodiesterase (PDE) Inhibitors Market 2024-2028

The phosphodiesterase (PDE) inhibitors market is forecasted to grow by USD 3.78 bn during 2023-2028, accelerating at a CAGR of 6.85% during the forecast period. The report on the phosphodiesterase (PDE) inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing adoption of poor lifestyle habits, rising prevalence of ed, and availability of next-generation PDE inhibitors.

Market Scope
Base Year	2023
End Year	2028
Series Year	2024-2028
Growth Momentum	Accelerate
YOY 2024	6.15%
CAGR	6.85%
Incremental Value	$3.78bn

Technavio's phosphodiesterase (PDE) inhibitors market is segmented as below:

By Application

Oral
Topical
Other RoA

By Type

PDE5 inhibitors
PDE4 inhibitors
PDE3 and others

By Geographical Landscape

North America
Europe
Asia
Rest of World (ROW)

This study identifies the application of new technologies for PDE inhibitors development as one of the prime reasons driving the phosphodiesterase (PDE) inhibitors market growth during the next few years. Also, growing geriatric population and rising burden of chronic diseases will lead to sizable demand in the market.

The report on the phosphodiesterase (PDE) inhibitors market covers the following areas:

Phosphodiesterase (PDE) inhibitors market sizing
Phosphodiesterase (PDE) inhibitors market forecast
Phosphodiesterase (PDE) inhibitors market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading phosphodiesterase (PDE) inhibitors market vendors that include AbbVie Inc., Amgen Inc., AstraZeneca Plc, Bayer AG, Boehringer Ingelheim International GmbH, Deciphera Pharmaceuticals Inc, Dong A Socio Holdings Co. Ltd., Dr Reddys Laboratories Ltd., Eli Lilly and Co., GlaxoSmithKline Plc, Merck KGaA, Novartis AG, Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., United Therapeutics Corp., Viatris Inc., VIVUS LLC, and Zydus Lifesciences Ltd.. Also, the phosphodiesterase (PDE) inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Product Code: IRTNTR73613

1 Executive Summary

1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Application
Exhibit 06: Executive Summary - Chart on Market Segmentation by Type
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

4.1 Global phosphodiesterase (PDE) inhibitors market 2018 - 2022
Exhibit 18: Historic Market Size - Data Table on global phosphodiesterase (pde) inhibitors market 2018 - 2022 ($ billion)
4.2 Application Segment Analysis 2018 - 2022
Exhibit 19: Historic Market Size - Application Segment 2018 - 2022 ($ billion)
4.3 Type Segment Analysis 2018 - 2022
Exhibit 20: Historic Market Size - Type Segment 2018 - 2022 ($ billion)
4.4 Geography Segment Analysis 2018 - 2022
Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
4.5 Country Segment Analysis 2018 - 2022
Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)

5 Five Forces Analysis

5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Application

6.1 Market segments
Exhibit 30: Chart on Application - Market share 2023-2028 (%)
Exhibit 31: Data Table on Application - Market share 2023-2028 (%)
6.2 Comparison by Application
Exhibit 32: Chart on Comparison by Application
Exhibit 33: Data Table on Comparison by Application
6.3 Oral - Market size and forecast 2023-2028
Exhibit 34: Chart on Oral - Market size and forecast 2023-2028 ($ billion)
Exhibit 35: Data Table on Oral - Market size and forecast 2023-2028 ($ billion)
Exhibit 36: Chart on Oral - Year-over-year growth 2023-2028 (%)
Exhibit 37: Data Table on Oral - Year-over-year growth 2023-2028 (%)
6.4 Topical - Market size and forecast 2023-2028
Exhibit 38: Chart on Topical - Market size and forecast 2023-2028 ($ billion)
Exhibit 39: Data Table on Topical - Market size and forecast 2023-2028 ($ billion)
Exhibit 40: Chart on Topical - Year-over-year growth 2023-2028 (%)
Exhibit 41: Data Table on Topical - Year-over-year growth 2023-2028 (%)
6.5 Other RoA - Market size and forecast 2023-2028
Exhibit 42: Chart on Other RoA - Market size and forecast 2023-2028 ($ billion)
Exhibit 43: Data Table on Other RoA - Market size and forecast 2023-2028 ($ billion)
Exhibit 44: Chart on Other RoA - Year-over-year growth 2023-2028 (%)
Exhibit 45: Data Table on Other RoA - Year-over-year growth 2023-2028 (%)
6.6 Market opportunity by Application
Exhibit 46: Market opportunity by Application ($ billion)
Exhibit 47: Data Table on Market opportunity by Application ($ billion)

7 Market Segmentation by Type

7.1 Market segments
Exhibit 48: Chart on Type - Market share 2023-2028 (%)
Exhibit 49: Data Table on Type - Market share 2023-2028 (%)
7.2 Comparison by Type
Exhibit 50: Chart on Comparison by Type
Exhibit 51: Data Table on Comparison by Type
7.3 PDE5 inhibitors - Market size and forecast 2023-2028
Exhibit 52: Chart on PDE5 inhibitors - Market size and forecast 2023-2028 ($ billion)
Exhibit 53: Data Table on PDE5 inhibitors - Market size and forecast 2023-2028 ($ billion)
Exhibit 54: Chart on PDE5 inhibitors - Year-over-year growth 2023-2028 (%)
Exhibit 55: Data Table on PDE5 inhibitors - Year-over-year growth 2023-2028 (%)
7.4 PDE4 inhibitors - Market size and forecast 2023-2028
Exhibit 56: Chart on PDE4 inhibitors - Market size and forecast 2023-2028 ($ billion)
Exhibit 57: Data Table on PDE4 inhibitors - Market size and forecast 2023-2028 ($ billion)
Exhibit 58: Chart on PDE4 inhibitors - Year-over-year growth 2023-2028 (%)
Exhibit 59: Data Table on PDE4 inhibitors - Year-over-year growth 2023-2028 (%)
7.5 PDE3 and others - Market size and forecast 2023-2028
Exhibit 60: Chart on PDE3 and others - Market size and forecast 2023-2028 ($ billion)
Exhibit 61: Data Table on PDE3 and others - Market size and forecast 2023-2028 ($ billion)
Exhibit 62: Chart on PDE3 and others - Year-over-year growth 2023-2028 (%)
Exhibit 63: Data Table on PDE3 and others - Year-over-year growth 2023-2028 (%)
7.6 Market opportunity by Type
Exhibit 64: Market opportunity by Type ($ billion)
Exhibit 65: Data Table on Market opportunity by Type ($ billion)

8 Customer Landscape

8.1 Customer landscape overview
Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
Exhibit 67: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibit 68: Data Table on Market share By Geographical Landscape 2023-2028 (%)
9.2 Geographic comparison
Exhibit 69: Chart on Geographic comparison
Exhibit 70: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2023-2028
Exhibit 71: Chart on North America - Market size and forecast 2023-2028 ($ billion)
Exhibit 72: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
Exhibit 73: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibit 74: Data Table on North America - Year-over-year growth 2023-2028 (%)
9.4 Europe - Market size and forecast 2023-2028
Exhibit 75: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibit 76: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibit 77: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibit 78: Data Table on Europe - Year-over-year growth 2023-2028 (%)
9.5 Asia - Market size and forecast 2023-2028
Exhibit 79: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibit 80: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibit 81: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibit 82: Data Table on Asia - Year-over-year growth 2023-2028 (%)
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
9.7 US - Market size and forecast 2023-2028
Exhibit 87: Chart on US - Market size and forecast 2023-2028 ($ billion)
Exhibit 88: Data Table on US - Market size and forecast 2023-2028 ($ billion)
Exhibit 89: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibit 90: Data Table on US - Year-over-year growth 2023-2028 (%)
9.8 Germany - Market size and forecast 2023-2028
Exhibit 91: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibit 92: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibit 93: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibit 94: Data Table on Germany - Year-over-year growth 2023-2028 (%)
9.9 UK - Market size and forecast 2023-2028
Exhibit 95: Chart on UK - Market size and forecast 2023-2028 ($ billion)
Exhibit 96: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
Exhibit 97: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibit 98: Data Table on UK - Year-over-year growth 2023-2028 (%)
9.10 China - Market size and forecast 2023-2028
Exhibit 99: Chart on China - Market size and forecast 2023-2028 ($ billion)
Exhibit 100: Data Table on China - Market size and forecast 2023-2028 ($ billion)
Exhibit 101: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibit 102: Data Table on China - Year-over-year growth 2023-2028 (%)
9.11 France - Market size and forecast 2023-2028
Exhibit 103: Chart on France - Market size and forecast 2023-2028 ($ billion)
Exhibit 104: Data Table on France - Market size and forecast 2023-2028 ($ billion)
Exhibit 105: Chart on France - Year-over-year growth 2023-2028 (%)
Exhibit 106: Data Table on France - Year-over-year growth 2023-2028 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 107: Market opportunity By Geographical Landscape ($ billion)
Exhibit 108: Data Tables on Market opportunity By Geographical Landscape ($ billion)

10 Drivers, Challenges, and Trends

10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 109: Impact of drivers and challenges in 2023 and 2028
10.4 Market trends

11 Vendor Landscape

11.1 Overview
11.2 Vendor landscape
Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 111: Overview on factors of disruption
11.4 Industry risks
Exhibit 112: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
Exhibit 113: Vendors covered
12.2 Market positioning of vendors
Exhibit 114: Matrix on vendor position and classification
12.3 Amgen Inc.
Exhibit 115: Amgen Inc. - Overview
Exhibit 116: Amgen Inc. - Product / Service
Exhibit 117: Amgen Inc. - Key offerings
12.4 AstraZeneca Plc
Exhibit 118: AstraZeneca Plc - Overview
Exhibit 119: AstraZeneca Plc - Product / Service
Exhibit 120: AstraZeneca Plc - Key news
Exhibit 121: AstraZeneca Plc - Key offerings
12.5 Bayer AG
Exhibit 122: Bayer AG - Overview
Exhibit 123: Bayer AG - Business segments
Exhibit 124: Bayer AG - Key news
Exhibit 125: Bayer AG - Key offerings
Exhibit 126: Bayer AG - Segment focus
12.6 Boehringer Ingelheim International GmbH
Exhibit 127: Boehringer Ingelheim International GmbH - Overview
Exhibit 128: Boehringer Ingelheim International GmbH - Business segments
Exhibit 129: Boehringer Ingelheim International GmbH - Key news
Exhibit 130: Boehringer Ingelheim International GmbH - Key offerings
Exhibit 131: Boehringer Ingelheim International GmbH - Segment focus
12.7 Dong A Socio Holdings Co. Ltd.
Exhibit 132: Dong A Socio Holdings Co. Ltd. - Overview
Exhibit 133: Dong A Socio Holdings Co. Ltd. - Product / Service
Exhibit 134: Dong A Socio Holdings Co. Ltd. - Key offerings
12.8 Dr Reddys Laboratories Ltd.
Exhibit 135: Dr Reddys Laboratories Ltd. - Overview
Exhibit 136: Dr Reddys Laboratories Ltd. - Business segments
Exhibit 137: Dr Reddys Laboratories Ltd. - Key offerings
Exhibit 138: Dr Reddys Laboratories Ltd. - Segment focus
12.9 Eli Lilly and Co.
Exhibit 139: Eli Lilly and Co. - Overview
Exhibit 140: Eli Lilly and Co. - Product / Service
Exhibit 141: Eli Lilly and Co. - Key news
Exhibit 142: Eli Lilly and Co. - Key offerings
12.10 GlaxoSmithKline Plc
Exhibit 143: GlaxoSmithKline Plc - Overview
Exhibit 144: GlaxoSmithKline Plc - Business segments
Exhibit 145: GlaxoSmithKline Plc - Key news
Exhibit 146: GlaxoSmithKline Plc - Key offerings
Exhibit 147: GlaxoSmithKline Plc - Segment focus
12.11 Pfizer Inc.
Exhibit 148: Pfizer Inc. - Overview
Exhibit 149: Pfizer Inc. - Product / Service
Exhibit 150: Pfizer Inc. - Key news
Exhibit 151: Pfizer Inc. - Key offerings
12.12 Sanofi SA
Exhibit 152: Sanofi SA - Overview
Exhibit 153: Sanofi SA - Business segments
Exhibit 154: Sanofi SA - Key news
Exhibit 155: Sanofi SA - Key offerings
Exhibit 156: Sanofi SA - Segment focus
12.13 Sun Pharmaceutical Industries Ltd.
Exhibit 157: Sun Pharmaceutical Industries Ltd. - Overview
Exhibit 158: Sun Pharmaceutical Industries Ltd. - Product / Service
Exhibit 159: Sun Pharmaceutical Industries Ltd. - Key offerings
12.14 Teva Pharmaceutical Industries Ltd.
Exhibit 160: Teva Pharmaceutical Industries Ltd. - Overview
Exhibit 161: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 162: Teva Pharmaceutical Industries Ltd. - Key news
Exhibit 163: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 164: Teva Pharmaceutical Industries Ltd. - Segment focus
12.15 United Therapeutics Corp.
Exhibit 165: United Therapeutics Corp. - Overview
Exhibit 166: United Therapeutics Corp. - Product / Service
Exhibit 167: United Therapeutics Corp. - Key offerings
12.16 Viatris Inc.
Exhibit 168: Viatris Inc. - Overview
Exhibit 169: Viatris Inc. - Business segments
Exhibit 170: Viatris Inc. - Key news
Exhibit 171: Viatris Inc. - Key offerings
Exhibit 172: Viatris Inc. - Segment focus
12.17 Zydus Lifesciences Ltd.
Exhibit 173: Zydus Lifesciences Ltd. - Overview
Exhibit 174: Zydus Lifesciences Ltd. - Business segments
Exhibit 175: Zydus Lifesciences Ltd. - Key offerings
Exhibit 176: Zydus Lifesciences Ltd. - Segment focus

13 Appendix

13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 177: Inclusions checklist
Exhibit 178: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 179: Currency conversion rates for US$
13.4 Research methodology
Exhibit 180: Research methodology
Exhibit 181: Validation techniques employed for market sizing
Exhibit 182: Information sources
13.5 List of abbreviations
Exhibit 183: List of abbreviations